scholarly journals Tightly spiral shaped bacteria in the human stomach: another cause of active chronic gastritis?

Gut ◽  
1990 ◽  
Vol 31 (2) ◽  
pp. 139-143 ◽  
Author(s):  
A Morris ◽  
M R Ali ◽  
L Thomsen ◽  
B Hollis
1979 ◽  
Vol 32 (3) ◽  
pp. 201-207 ◽  
Author(s):  
J M Sloan ◽  
K D Buchanan ◽  
R J McFarland ◽  
P Titterington ◽  
J C Sandford

2011 ◽  
Vol 57 (5) ◽  
pp. 1238-1246 ◽  
Author(s):  
Shuji Takiguchi ◽  
Shinichi Adachi ◽  
Kazuyoshi Yamamoto ◽  
Eiichi Morii ◽  
Hiroshi Miyata ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A607-A607
Author(s):  
N BROUTET ◽  
M PLEBANI ◽  
C SAKAROVITCH ◽  
P SIPPONEN

2001 ◽  
Vol 120 (5) ◽  
pp. A656-A656
Author(s):  
M CAVICCHI ◽  
J AUROUX ◽  
J NHIEU ◽  
J DELCHIER ◽  
D LAMARQUE

2019 ◽  
Author(s):  
M Kadi ◽  
M Eljihad ◽  
M Tahiri Joutei-Hassani ◽  
W Badre ◽  
W Hliwa ◽  
...  

2019 ◽  
pp. 28-32
Author(s):  
Van Huy Tran

Background and aims: Efficacy with substitution of tetracycline with amoxicillin, an antibiotics having a very low resistance rate and a high tolerability, in bismuth quadruple therapy (BQT) have not been studied in Vietnam. Our study aimed to evaluate the efficacy and tolerability of modified BQT vs. standard BQT for first-line Helicobacter pylori eradication. Patients and methods: This is a randomized, prospective study. 120 patients with H.pylori positive-chronic gastritis were randomly divided into two groups. The RBMA group containing rabeprazole 20 mg, bismuth subsalicylic 524mg, metronidazole 500mg, amoxicillin 1000mg, all 2 times a day, for 14 days. The RBMT group received rabeprazole, bismuth subsalicylic, metronidazole and tetracycline. Evaluation for compliance and drug-related side effects were evaluated at the end of two weeks. 4-6 weeks after the end of treatment, the H.pylori eradication rate was determined by the C13urease breath test. Results: Eradication rate was not statistically significative different between the RBMA and the RBMT: 91.2%; 95% confidence interval, 78.2% - 96.7%) vs. 90%; 95% CI, 81.6% - 96.3%) by per-protocol analysis (p = 0.42) and 86.7% (95%CI, 75.84% - 93.09%) vs. 75% (95%CI, 62.1% - 85.3%) by intention-to-treat analysis (ITT, p = 0.06). Adverse effects were significant higher in the RBMT group than in the RBMA group (48.3% vs. 26.7%; p = 0.071) and rate of good compliance was significantly higher in RBMA group than in RBMT group (p < 0.05). Conclusion: The modified BQT including rabeprazole, bismuth, metronidazole and amoxicillin achieved a fairly high rate of H.pylori infection eradication with a higher compliance and lower rate of adverse effects compared to the BQT in patients with chronic gastritis. Further studies need to conduct to confirm this new regimens as a first-line therapy in our country. Key words: Modified bismuth quadruple therapy, BQT, Helicobacter pylori eradication


Sign in / Sign up

Export Citation Format

Share Document